Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
90 hedge funds and large institutions have $50.6M invested in Marinus Pharmaceuticals, Inc in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 24 increasing their positions, 28 reducing their positions, and 54 closing their positions.
367% more call options, than puts
Call options by funds: $406K | Put options by funds: $87K
14% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 28
20% less funds holding
Funds holding: 112 → 90 (-22)
41% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 54
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
90% less capital invested
Capital invested by funds: $486M → $50.6M (-$436M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$12M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$6.99M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$6.88M |
| 4 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$2.19M |
| 5 |
Millennium Management
New York
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$37.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$29.4M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$21.2M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$21.1M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
-$14.7M |
MRNS Hedge Fund Activity: Q2 2024 in Review
90 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2024, worth a combined $50.6M — down 90% from $486M a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of MRNS and 32 opened new positions — a net loss of 22 holders — while 28 trimmed existing stakes and 24 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $12M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $37.4M sold.
- 90 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2024, down from 112 in Q1 2024.
- Funds reported $50.6M of Marinus Pharmaceuticals, Inc stock for Q2 2024, down 90% quarter-over-quarter.
- 32 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2024 and 54 closed out, a net change of -22 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q2 2024 was Tang Capital Management, an estimated $12M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q2 2024 was Avoro Capital Advisors, an estimated $37.4M sold.
Based on aggregated 13F filings for Q2 2024.